have important implications for the individual tailoring of therapy in patients with AF. I first prescribed amiodarone about 30 years ago, before it was approved for use in the US. Back then we ...
Amiodarone-induced thyrotoxicosis (AIT) remains a challenging problem, often posing difficulties in diagnosis and therapy. Two types of AIT exist and are classified according to their etiology.
In view of the life-threatening nature of the patient's arrhythmia, amiodarone therapy was continued and thionamide (carbimazole) treatment was commenced. AIT has been classified into two types.
At that time the patient began therapy with amiodarone (200 mg by mouth daily). His symptoms resolved and he tolerated the drug without any complications. There was no personal or family history ...
may be subtle initially and is the most common cause of death related to amiodarone therapy. It can take months to years to develop and occurs in about 1% to 5% of patients taking 200 mg daily ...
MEDLINE 9. Hermida JS, Jarry G, Tcheng E et al.: Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced ...
Significant bluish discoloration of the skin can is seen. Discontinuing amiodarone therapy frequently improves the discoloration. The etiology is not clear.